KPC-9, a novel carbapenemase from clinical specimens in Israel

  • Carlos Hidalgo-Grass
  • , Gabriela Warburg
  • , Violeta Temper
  • , Shmuel Benenson
  • , Allon E. Moses
  • , Colin Block
  • , Jacob Strahilevitz*
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

A blaKPC-9 carbapenemase variant was discovered in isolates of Klebsiella pneumoniae and Escherichia coli from a single patient. It differed from blaKPC-3 by one amino acid substitution (Val239Ala). The K. pneumoniae isolate was typed as ST258, as was the epidemic Israeli KPC-3 clone. blaKPC-9 was found on a plasmid indistinguishable from pKpQIL that carries blaKPC-3 in the epidemic clone. Compared to KPC-3, KPC-9 conferred less resistance to carbapenems and higher resistance to ceftazidime.

Original languageEnglish
Pages (from-to)6057-6059
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume56
Issue number11
DOIs
StatePublished - Nov 2012
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'KPC-9, a novel carbapenemase from clinical specimens in Israel'. Together they form a unique fingerprint.

Cite this